The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Pulmonary hypertension (PH) is now recognized as a complication of both chronic and acquired hemolytic anemias. The process of hemolysis appears to be central to disease pathogenesis. Sickle cell disease (SCD), a congenital hemoglobinopathy affecting as many as 30 million individuals worldwide, is the best characterized hemolytic anemia associated with PH. Multiple clinical studies have demonstrated...
Summary The first-generation hemoglobin therapeutics,most of which were created more than 10 years ago, were designed to make a solution that looked identical to hemoglobin contained within a red blood cell. Numerous issues have been raised with their experimental use such as pulmonary and systemic vasoactivity, extravasation of hemoglobin, serum enzyme increases, adverse effects on gastrointestinal...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.